Skip to content
10-Q

Quarterly Report

Theravance Biopharma, Inc. TBPH

0001104659-25-110382

← back to feed
Filed
Nov 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 3, 2025 50.67M sh
Shares Diluted Q3 2025 · Sep 30, 2025 51.91M sh
Shares Diluted Q3 2025 · Sep 30, 2025 50.98M sh
Shares Diluted Q3 2025 · Sep 30, 2024 49.04M sh
Shares Diluted Q3 2025 · Sep 30, 2024 48.69M sh
Operating Cash Flow Q3 2025 · Sep 30, 2025 $244.61M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$10.63M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $174.77M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $37.8M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $23.38M
Stockholders Equity Q3 2025 · Sep 30, 2025 $232.68M
Stockholders Equity Q3 2025 · Jun 30, 2025 $224.85M
Stockholders Equity Q3 2025 · Dec 31, 2024 $175.55M
Stockholders Equity Q3 2025 · Sep 30, 2024 $185.65M
Stockholders Equity Q3 2025 · Jun 30, 2024 $193.69M
Stockholders Equity Q3 2025 · Dec 31, 2023 $213M
Current Liabilities Q3 2025 · Sep 30, 2025 $37.41M
Current Liabilities Q3 2025 · Dec 31, 2024 $32.09M
Current Assets Q3 2025 · Sep 30, 2025 $354.7M
Current Assets Q3 2025 · Dec 31, 2024 $161.07M
Total Assets Q3 2025 · Sep 30, 2025 $415.46M
Total Assets Q3 2025 · Dec 31, 2024 $354.16M
Eps Diluted Q3 2025 · Sep 30, 2025 $0.07
Eps Diluted Q3 2025 · Sep 30, 2025 $0.88
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.26
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.84
Eps Basic Q3 2025 · Sep 30, 2025 $0.07
Eps Basic Q3 2025 · Sep 30, 2025 $0.89
Eps Basic Q3 2025 · Sep 30, 2024 −$0.26
Eps Basic Q3 2025 · Sep 30, 2024 −$0.84
Sga Expense Q3 2025 · Sep 30, 2025 $18.33M
Sga Expense Q3 2025 · Sep 30, 2025 $55.13M
Sga Expense Q3 2025 · Sep 30, 2024 $16.88M
Sga Expense Q3 2025 · Sep 30, 2024 $50.67M
Rd Expense Q3 2025 · Sep 30, 2025 $8.11M
Rd Expense Q3 2025 · Sep 30, 2025 $30.05M
Rd Expense Q3 2025 · Sep 30, 2024 $9.27M
Rd Expense Q3 2025 · Sep 30, 2024 $28.19M
Net Income Q3 2025 · Sep 30, 2025 $3.62M
Net Income Q3 2025 · Sep 30, 2025 $44.87M
Net Income Q3 2025 · Sep 30, 2024 −$12.7M
Net Income Q3 2025 · Sep 30, 2024 −$40.89M
Operating Income Q3 2025 · Sep 30, 2025 −$6.46M
Operating Income Q3 2025 · Sep 30, 2025 −$23.61M
Operating Income Q3 2025 · Sep 30, 2024 −$10.84M
Operating Income Q3 2025 · Sep 30, 2024 −$37.75M
Revenue Q3 2025 · Sep 30, 2025 $19.99M
Revenue Q3 2025 · Sep 30, 2025 $61.57M
Revenue Q3 2025 · Sep 30, 2024 $16.87M
Revenue Q3 2025 · Sep 30, 2024 $45.63M
Stock Repurchased Q3 2025 · Sep 30, 2024 $445K